CYP2D6 genotyping
Jump to navigation
Jump to search
Indications
Laboratory
Clinical significance
- cytochrome P450 2D6 activates tamoxifen to 4-hydroxy-N-desmethyl-tamoxifen (endoxifen) the most active metabolite of tamoxifen (in terms of estrogen binding
- individuals with homozygous mutations may be poor metabolizers of tamoxifen; thus poor activators of tamoxifen & poor responders to therapy
- apparently the may be ultra-rapid metabolizer forms as well[2]
More general terms
Additional terms
- cytochrome P450 2D6 (cytochrome P450 2D, cytochrome P450 DB1, debrisoquine-4-hydroxylase, CYP2D6)
- tamoxifen (Novaldex, Soltamox)
Component of
References
- ↑ Cytochrome P450 2D6 Genotype for Tamoxifen Hormonal Therapy Mayo Clinic http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/87966
- ↑ 2.0 2.1 2.2 ARUP Consult: CYP2D6 Genotyping - Tamoxifen deorecated reference
- ↑ 3.0 3.1 Kuznar W Guidance Issued for Tamoxifen Based on CYP2D6 Genotyping. Poor metabolizers may require increase in dose or a switch to an aromatase inhibitor. MedPage Today. ASCO Reading Room 03.20.2018 https://www.medpagetoday.com/reading-room/asco/breast-cancer/71868
Goetz MP, Sangkuhl K, Guchelaar HJ, et al Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy Clin Pharmacol Ther. 2018 Jan 31 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29385237